Celldex Therapeutics Inc Cash Flow Conversion Efficiency
Celldex Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) has a cash flow conversion efficiency ratio of -0.144x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.59 Million) by net assets ($456.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Celldex Therapeutics Inc (1986–2025)
Cash flow conversion efficiency of Celldex Therapeutics Inc from 1986 to 2025. This chart illustrates how Celldex Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Celldex Therapeutics Inc for real-time trading data and today's change.
Celldex Therapeutics Inc Cash Flow Conversion Ratio Explained
Celldex Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Celldex Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Celldex Therapeutics Inc ranked by their cash flow conversion efficiency. Also see market cap of Celldex Therapeutics Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northeast Securities Co Ltd
SHE:000686
|
-0.013x |
|
Wisdom Marine Lines Co Ltd
TW:2637
|
0.055x |
|
ADEIA CORP
NASDAQ:ADEA
|
0.114x |
|
Tofas Turk Otomobil Fabrikasi AS
IS:TOASO
|
-0.093x |
|
Hyundai Mar&Fi
KO:001450
|
0.051x |
|
Euronet Worldwide Inc
NASDAQ:EEFT
|
0.021x |
|
ShenZhen Special Economic Zone Real Estate & Properties Group Co Ltd
SHE:000029
|
-0.001x |
|
Boyd Group Services Inc.
TO:BYD
|
0.121x |
Annual Cash Flow Conversion Efficiency for Celldex Therapeutics Inc (1986–2025)
The table below shows the annual cash flow conversion efficiency of Celldex Therapeutics Inc from 1986 to 2025. Review CLDX cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $527.16 Million | $-210.94 Million | -0.400x | -89.45% |
| 2024-12-31 | $747.00 Million | $-157.78 Million | -0.211x | +15.51% |
| 2023-12-31 | $429.17 Million | $-107.29 Million | -0.250x | +21.38% |
| 2022-12-31 | $326.20 Million | $-103.73 Million | -0.318x | -119.00% |
| 2021-12-31 | $419.48 Million | $-60.91 Million | -0.145x | +24.76% |
| 2020-12-31 | $209.36 Million | $-40.40 Million | -0.193x | +60.90% |
| 2019-12-31 | $94.03 Million | $-46.41 Million | -0.494x | +18.60% |
| 2018-12-31 | $124.06 Million | $-75.23 Million | -0.606x | -43.44% |
| 2017-12-31 | $236.37 Million | $-99.93 Million | -0.423x | +0.72% |
| 2016-12-31 | $265.43 Million | $-113.04 Million | -0.426x | -24.93% |
| 2015-12-31 | $290.11 Million | $-98.89 Million | -0.341x | +28.94% |
| 2014-12-31 | $211.66 Million | $-101.54 Million | -0.480x | -126.71% |
| 2013-12-31 | $319.80 Million | $-67.67 Million | -0.212x | +59.29% |
| 2012-12-31 | $95.77 Million | $-49.78 Million | -0.520x | -0.18% |
| 2011-12-31 | $68.72 Million | $-35.66 Million | -0.519x | -28.57% |
| 2010-12-31 | $75.25 Million | $-30.37 Million | -0.404x | +0.33% |
| 2009-12-31 | $73.77 Million | $-29.87 Million | -0.405x | -140.17% |
| 2008-12-31 | $18.13 Million | $18.28 Million | 1.008x | -0.54% |
| 2007-12-31 | $-19.04 Million | $-19.30 Million | 1.014x | -91.89% |
| 2006-12-31 | $2.16 Million | $27.00 Million | 12.494x | +4437.96% |
| 2005-12-31 | $20.89 Million | $-6.02 Million | -0.288x | -6.91% |
| 2004-12-31 | $38.41 Million | $-10.35 Million | -0.269x | +35.92% |
| 2003-12-31 | $27.92 Million | $-11.74 Million | -0.420x | +20.89% |
| 2002-12-31 | $31.34 Million | $-16.66 Million | -0.531x | -15.53% |
| 2001-12-31 | $45.27 Million | $-20.83 Million | -0.460x | -459.83% |
| 2000-12-31 | $53.93 Million | $-4.43 Million | -0.082x | +83.24% |
| 1999-12-31 | $17.41 Million | $-8.54 Million | -0.490x | -3.59% |
| 1998-12-31 | $18.80 Million | $-8.90 Million | -0.473x | +61.27% |
| 1997-12-31 | $6.30 Million | $-7.70 Million | -1.222x | -96.56% |
| 1996-12-31 | $15.60 Million | $-9.70 Million | -0.622x | -25.93% |
| 1995-12-31 | $16.00 Million | $-7.90 Million | -0.494x | +4.51% |
| 1994-12-31 | $17.60 Million | $-9.10 Million | -0.517x | -173.56% |
| 1993-12-31 | $29.10 Million | $-5.50 Million | -0.189x | +3.08% |
| 1992-12-31 | $20.00 Million | $-3.90 Million | -0.195x | +32.40% |
| 1991-12-31 | $10.40 Million | $-3.00 Million | -0.288x | 0.00% |
| 1990-12-31 | $10.40 Million | $-3.00 Million | -0.288x | -439.84% |
| 1989-12-31 | $13.10 Million | $-700.00K | -0.053x | +35.88% |
| 1988-12-31 | $8.40 Million | $-700.00K | -0.083x | -107.05% |
| 1986-12-31 | $10.40 Million | $12.30 Million | 1.183x | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more